1. Home
  2. BLIN vs AKTX Comparison

BLIN vs AKTX Comparison

Compare BLIN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLIN
  • AKTX
  • Stock Information
  • Founded
  • BLIN 2000
  • AKTX N/A
  • Country
  • BLIN United States
  • AKTX United States
  • Employees
  • BLIN N/A
  • AKTX N/A
  • Industry
  • BLIN EDP Services
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLIN Technology
  • AKTX Health Care
  • Exchange
  • BLIN Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • BLIN 15.9M
  • AKTX 17.2M
  • IPO Year
  • BLIN 2007
  • AKTX N/A
  • Fundamental
  • Price
  • BLIN $0.95
  • AKTX $0.46
  • Analyst Decision
  • BLIN Strong Buy
  • AKTX Strong Buy
  • Analyst Count
  • BLIN 1
  • AKTX 2
  • Target Price
  • BLIN $4.62
  • AKTX $3.30
  • AVG Volume (30 Days)
  • BLIN 48.5K
  • AKTX 474.3K
  • Earning Date
  • BLIN 12-22-2025
  • AKTX 11-13-2025
  • Dividend Yield
  • BLIN N/A
  • AKTX N/A
  • EPS Growth
  • BLIN N/A
  • AKTX N/A
  • EPS
  • BLIN N/A
  • AKTX N/A
  • Revenue
  • BLIN $15,375,000.00
  • AKTX N/A
  • Revenue This Year
  • BLIN $2.45
  • AKTX N/A
  • Revenue Next Year
  • BLIN $16.36
  • AKTX N/A
  • P/E Ratio
  • BLIN N/A
  • AKTX N/A
  • Revenue Growth
  • BLIN 0.54
  • AKTX N/A
  • 52 Week Low
  • BLIN $0.90
  • AKTX $0.42
  • 52 Week High
  • BLIN $2.80
  • AKTX $1.73
  • Technical
  • Relative Strength Index (RSI)
  • BLIN 25.25
  • AKTX 30.25
  • Support Level
  • BLIN $0.90
  • AKTX $0.46
  • Resistance Level
  • BLIN $1.00
  • AKTX $0.55
  • Average True Range (ATR)
  • BLIN 0.07
  • AKTX 0.07
  • MACD
  • BLIN -0.02
  • AKTX -0.01
  • Stochastic Oscillator
  • BLIN 10.92
  • AKTX 7.56

About BLIN Bridgeline Digital Inc.

Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: